Company Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 12, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Geoffrey Dow |
Contact Details
Address: 1025 Connecticut Avenue NW, Suite 1000 Washington, District of Columbia 20036 United States | |
| Phone | 202 327 5422 |
| Website | 60degreespharma.com |
Stock Details
| Ticker Symbol | SXTP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.30 |
| CIK Code | 0001946563 |
| CUSIP Number | 83006G104 |
| ISIN Number | US83006G1040 |
| Employer ID | 45-2406880 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geoffrey Stuart Dow | Chairman, Chief Executive Officer and President |
| Tyrone Miller | Chief Financial Officer and Treasurer |
| Kristen Landon | Chief Commercial Officer |
| Dr. Bryan Smith | Chief Medical Officer |
| Jennifer Herz | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 12, 2025 | D | Notice of Exempt Offering of Securities |
| Feb 11, 2025 | D | Notice of Exempt Offering of Securities |
| Feb 11, 2025 | SCHEDULE 13G | Filing |
| Feb 6, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 424B5 | Filing |
| Feb 3, 2025 | SCHEDULE 13G | Filing |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 424B5 | Filing |